查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
視網膜疾病治療市場 - 2018-2028 年全球行業規模、佔有率、趨勢、機會和預測，按類型、劑型、配銷通路、地區和競爭細分
市場調查報告書
商品編碼
1326472

視網膜疾病治療市場 - 2018-2028 年全球行業規模、佔有率、趨勢、機會和預測，按類型、劑型、配銷通路、地區和競爭細分

Retinal Disorder Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Type, By Dosage Form, By Distribution Channel, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 112 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

由於視網膜疾病患病率不斷增加、人口老齡化、醫療保健技術的進步以及醫療保健支出的增加等，預計全球視網膜疾病治療市場在預測期內將以驚人的速度成長。人口老齡化是推動視網膜疾病治療市場的另一個因素。隨著人們年齡的成長，患 AMD 和糖尿病視網膜病變等視網膜疾病的風險也會增加。根據國家眼科研究所的數據，AMD 的患病率從 50-59 歲人群的 2% 增加到 75 歲及以上人群的 30%。隨著全球人口老齡化，這一趨勢預計將持續下去，從而支持未來幾年全球視網膜疾病治療市場的成長。

視網膜疾病的患病率不斷上升

視網膜疾病是一組影響視網膜（眼睛後部的感光組織）的疾病。這些疾病會導致一系列症狀，從輕度視力障礙到完全失明，是全世界視力障礙的主要原因。據世界衛生組織稱，全球估計有 2.53 億人患有視力障礙，其中 3600 萬人失明。視網膜疾病是造成這些數位的一個重要原因，其中年齡相關性黃斑部病變、糖尿病性視網膜病變和視網膜脫離等疾病是視力障礙和失明的最常見原因。

年齡相關性黃斑部病變 (AMD) 是一種主要影響老年人的視網膜進行性變性，是已開發國家視力障礙的主要原因。據美國眼科學會稱，美國估計有 1100 萬人患有某種形式的 AMD，隨著人口老齡化，這一數位預計還會增加。糖尿病視網膜病變是糖尿病的一種併發症，可導致視網膜進行性損傷，是全世界視力障礙和失明的另一個常見原因。據國際糖尿病聯盟稱，全球估計有4.63 億人患有糖尿病，預計到2045 年這一數位將增至7 億。其中，多達三分之一的人面臨患糖尿病視網膜病變的風險，估計三分之一的人面臨患糖尿病視網膜病變的風險。糖尿病患者已經出現某種形式的視力喪失。其他視網膜疾病，例如視網膜脫離和色素性視網膜炎，雖然不太常見，但仍然會對人的視力和生活品質產生重大影響。視網膜脫離（視網膜與下方組織的分離）大約影響每10,000 人中就有一個，而色素性視網膜炎（一種導致進行性視力喪失的遺傳性疾病）估計每3,000 至4,000 人中就有一個受到影響。人群中視網膜疾病患病率的增加將導致治療需求的增加，從而推動全球視網膜疾病治療市場的成長。

醫療保健技術的進步

醫療保健技術的進步正在推動全球視網膜疾病治療市場。新的療法和技術不斷湧現，為視網膜疾病患者提供了更好的治療效果。例如，抗血管內皮生長因子（抗 VEGF）療法徹底改變了 AMD 的治療方法，有助於減緩疾病的進展並改善視力。此外，視網膜植入物和輔助設備為嚴重視力喪失的患者提供了新的選擇，從而支持了全球視網膜疾病治療市場的成長。

此外，虛擬實境（VR）和擴增實境（AR）等輔助技術正在開發中，以幫助患有視網膜疾病的患者。這些技術可以模擬視覺環境並提供反饋以幫助患者駕馭周圍環境。例如，VR耳機可以模擬繁忙的街道，讓患者練習安全過馬路。反過來，預計這將為未來幾年全球視網膜疾病治療市場的成長創造利潤豐厚的機會。

政府支持舉措

視網膜疾病是全世界視力障礙和失明的主要原因，影響所有年齡段和人口統計的人群。雖然有幾種有效的視網膜疾病治療方法，但不同國家和地區獲得這些治療方法的情況差異很大。在美國、加拿大和西歐大部分地區等已開發國家，視網膜疾病的治療通常已經很成熟並且得到廣泛應用。然而，在發展中國家，獲得視網膜疾病治療的機會往往因缺乏資源、基礎設施和訓練有素的醫療保健專業人員而受到限制。這些國家的許多視網膜疾病患者無法獲得所需的護理，導致視力喪失和失明的發生率更高。

為了解決這種差距，已經建立了一些組織和政府舉措來改善發展中國家獲得視網膜疾病治療的機會。其中一項舉措是世界衛生組織的“2020 年願景”計劃，該計劃旨在到2020 年消除可避免的失明。該計劃的重點是改善發展中國家獲得眼保健服務的機會，包括與視網膜疾病相關的服務。同樣，在中國，政府啟動了一項全國性計劃，以改善獲得眼保健服務的機會，包括與視網膜疾病相關的服務。該計劃包括在全國建立300多家專業眼科醫院，以及培訓數千名眼科醫生和其他眼保健專業人員。此外，在印度，政府制定了多項國家計劃，為服務不足的人群提供免費或低成本的眼保健服務。這些計劃包括流動眼科診所、遠程醫療服務以及白內障手術和其他眼科手術的補貼。此外，美國國家眼科研究所資助視網膜疾病研究，並為患者和醫療保健專業人員提供資源。不同組織和政府採取的此類舉措將增加人們獲得有效視網膜治療的機會，從而推動全球視網膜疾病治療市場的成長。

最近的發展

  • 2017年，美國食品和藥物管理局批准了第一個針對一種名為萊伯先天性黑蒙的遺傳性視網膜疾病的基因療法。這種名為 Luxturna 的療法使用病毒將缺陷基因的健康副本傳遞到視網膜，從而可以改善患有該疾病的人的視力。從那時起，其他幾種治療視網膜疾病的基因療法已經在臨床試驗中進行了測試，並取得了有希望的結果。
  • 2019年，加州大學洛杉磯分校的研究團隊宣布，他們已成功利用幹細胞恢復視網膜退化小鼠的視力。研究人員希望在不久的將來開始人體臨床試驗。
  • 2019年，美國食品和藥物管理局批准了一種名為Beovu的新藥，用於治療濕性年齡相關性黃斑部病變，這是一種常見的視網膜疾病，可導致視力喪失。 Beovu 的工作原理是針對一種名為 VEGF 的蛋白質，這種蛋白質會導致視網膜中血管異常生長。該藥物已被證明可以有效減少濕性年齡相關性黃斑部病變患者的疾病進展並改善視力。

可用的客製化：

根據給定的市場數據，TechSci Research 可根據公司的具體需求提供客製化服務。該報告可以使用以下自定義選項：

公司資訊

  • 其他市場參與者（最多五個）的詳細分析和概況分析。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 考慮學習的年份
    • 主要市場細分

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要行業合作夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量和驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球視網膜疾病治療市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按類型（黃斑部病變、糖尿病視網膜病變、其他）
    • 按劑型（凝膠、眼液、膠囊和片劑、滴眼劑、其他）
    • 按配銷通路（醫院藥房、網上藥房、零售藥房）
    • 按地區
    • 按公司分類 (2022)
  • 產品圖
    • 按類型
    • 按劑型分類
    • 按配銷通路
    • 按地區

第 6 章：北美視網膜疾病治療市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按類型
    • 按劑型分類
    • 按配銷通路
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲視網膜疾病治療市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按類型
    • 按劑型分類
    • 按配銷通路
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太地區視網膜疾病治療市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按類型
    • 按劑型分類
    • 按配銷通路
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳大利亞

第 9 章：南美洲視網膜疾病治療市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按類型
    • 按劑型分類
    • 按配銷通路
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲視網膜疾病治療市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按類型
    • 按劑型分類
    • 按配銷通路
    • 按國家/地區
  • MEA：國家分析
    • 南非視網膜疾病治療
    • 沙烏地阿拉伯視網膜疾病治療
    • 阿拉伯聯合大公國視網膜疾病治療

第 11 章：市場動態

  • 司機
  • 挑戰

第 12 章：市場趨勢與發展

  • 近期發展
  • 併購
  • 類型發布

第 13 章：全球視網膜疾病治療市場：SWOT 分析

第 14 章：波特的五力分析

  • 行業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代類型的威脅

第15章：競爭格局

  • 商業概覽
  • 產品類型
  • 最近的發展
  • 主要人員
  • SWOT分析
    • Santen Pharmaceutical Co. Ltd.
    • Regeneron Pharmaceuticals Inc.
    • Graybug Vision, Inc.
    • Shire (Takeda Pharmaceutical Company Limited)
    • Bayer AG
    • Genentech, Inc.
    • Acucela Inc.
    • Pfizer, Inc.
    • Kubota Pharmaceutical Holdings Co., Ltd.
    • Allergan plc. (AbbVie Inc.)

第 16 章：戰略建議

簡介目錄
Product Code: 14867

Global Retinal Disorder Treatment Market is expected to grow at an impressive rate during the forecast period on account of the increasing prevalence of retinal disorders, the aging population, advancements in healthcare technology, and rising healthcare expenditure, among others. The aging population is another factor driving the retinal disorder treatment market. As people age, their risk of developing retinal disorders such as AMD and diabetic retinopathy increases. According to the National Eye Institute, the prevalence of AMD increases from 2% in people aged 50-59 years to 30% in people aged 75 years and older. This trend is expected to continue as the global population ages, thereby supporting the growth of global retinal disorder treatment market for the next few years.

Additionally, increasing research and development activities by various companies operating in the market and academic & research institutions across the globe for the identification and development of new treatments for retinal disorders or to improve the safety and efficacy of existing treatments is expected to create lucrative opportunities for the growth of global retinal disorder treatment market during the forecast period. According to clinicaltrials.gov, as of March 2023, there are around 1,198 studies in different phases of development related to retinal disorders treatment across the globe.

Rising healthcare expenditure is another factor driving the global retinal disorder treatment market. As healthcare expenditure increases, more resources are being dedicated to the development and commercialization of new therapies and technologies for retinal disorders. According to the National Health Expenditure Account, total healthcare expenditure in the United States reached USD 3.8 trillion in 2019.

Growing Prevalence of Retinal Disorders

Retinal disorders are a group of conditions that affect the retina, the light-sensitive tissue at the back of the eye. These conditions can cause a range of symptoms, from mild vision impairment to complete blindness, and are a leading cause of visual impairment worldwide. According to the World Health Organization, an estimated 253 million people worldwide live with visual impairment, of whom 36 million are blind. Retinal disorders are a significant contributor to these numbers, with conditions such as age-related macular degeneration, diabetic retinopathy, and retinal detachment among the most common causes of visual impairment and blindness.

Age-related macular degeneration (AMD), a progressive degeneration of the retina that affects mostly older adults, is a leading cause of visual impairment in developed countries. According to the American Academy of Ophthalmology, an estimated 11 million people in the United States have some form of AMD, with that number expected to increase as the population ages. Diabetic retinopathy, a complication of diabetes that can cause progressive damage to the retina, is another common cause of visual impairment and blindness worldwide. According to the International Diabetes Federation, an estimated 463 million people worldwide have diabetes, with that number expected to rise to 700 million by 2045. Of these, up to one-third are at risk of developing diabetic retinopathy, with an estimated one in three people with diabetes already experiencing some form of vision loss. Other retinal disorders, such as retinal detachment and retinitis pigmentosa, are less common but can still have a significant impact on a person's vision and quality of life. Retinal detachment, a separation of the retina from the underlying tissue, affects approximately one in every 10,000 people, while retinitis pigmentosa, a genetic disorder that causes progressive vision loss, affects an estimated one in every 3,000 to 4,000 people. The increasing prevalence of retinal disorders among the population will contribute to an increase in demand for treatments, thereby driving the growth of global retinal disorder treatment market.

Advancements in Healthcare Technology

Advancements in healthcare technology are driving the global retinal disorder treatment market. New therapies and technologies are emerging that offer improved outcomes for patients with retinal disorders. For example, anti-vascular endothelial growth factor (anti-VEGF) therapy has revolutionized the treatment of AMD, helping to slow the progression of the disease and improve vision. Additionally, retinal implants and assistive devices are providing new options for patients with severe vision loss, in turn supporting the growth of global retinal disorder treatment market.

Additionally, assistive technologies such as virtual reality (VR) and augmented reality (AR) are being developed to help patients with retinal disorders. These technologies can simulate visual environments and provide feedback to help patients navigate their surroundings. For example, a VR headset can simulate a busy street, allowing patients to practice crossing the road safely. This, in turn, is expected to create lucrative opportunities for the growth of global retinal disorders treatment market in the next few years.

Supportive Government Initiatives

Retinal disorders are a major cause of visual impairment and blindness worldwide, affecting people of all ages and demographics. While there are several effective treatments available for retinal disorders, access to these treatments varies widely across different countries and regions. In developed countries such as the United States, Canada, and much of Western Europe, retinal disorder treatment is generally well-established and widely available. In developing countries, however, access to retinal disorder treatment is often limited by a lack of resources, infrastructure, and trained healthcare professionals. Many people with retinal disorders in these countries are unable to receive the care they need, leading to a higher incidence of vision loss and blindness.

To address this disparity, several organizations and government initiatives have been established to improve access to retinal disorder treatment in developing countries. One such initiative was the World Health Organization's Vision 2020 program, which aimed to eliminate avoidable blindness by the year 2020. The program focused on improving access to eye care services in developing countries, including those related to retinal disorders. Similarly, in China, the government has launched a nationwide program to improve access to eye care services, including those related to retinal disorders. The program includes the establishment of more than 300 specialized eye hospitals across the country, as well as the training of thousands of ophthalmologists and other eye care professionals. Additionally, in India, the government has established several national programs to provide free or low-cost eye care services to underserved populations. These programs include mobile eye clinics, telemedicine services, and subsidies for cataract surgery and other eye surgeries. Also, the National Eye Institute in the US funds research on retinal disorders and provides resources for patients and healthcare professionals. Such initiatives taken by different organizations and governments will increase the access of people to effective retinal treatment, thereby driving the growth of global retinal disorder treatment market.

Market Segmentation

Global Retinal Disorder Treatment Market can be segmented by type, dosage form, distribution channel, and by region. Based on type, Global Retinal Disorder Treatment market can be categorized into macular degeneration, diabetic retinopathy, and others. By dosage form, the Global Retinal Disorder Treatment market can be segmented into gels, eye solutions, capsules & tablets, eye drops, and others. By distribution channel, the Global Retinal Disorder Treatment market can be fragmented into hospital pharmacies, online pharmacy, and retail pharmacies. Regionally, the global Retinal Disorder Treatment market can be segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa.

Market Players

Santen Pharmaceutical Co. Ltd., Regeneron Pharmaceuticals Inc., Graybug Vision, Inc., Shire (Takeda Pharmaceutical Company Limited), Bayer AG, Genentech, Inc., Acucela Inc., Pfizer, Inc., Kubota Pharmaceutical Holdings Co., Ltd., Allergan plc. (AbbVie Inc.), among others, are some of the leading players operating in the global Retinal Disorder Treatment market.

Recent Developments

  • In 2017, the U.S. Food and Drug Administration approved the first gene therapy for an inherited retinal disorder called Leber congenital amaurosis. This therapy, called Luxturna, uses a virus to deliver a healthy copy of a defective gene to the retina, which can improve vision in people with the disorder. Since then, several other gene therapies for retinal disorders have been tested in clinical trials with promising results.
  • In 2019, a team of researchers at the University of California, Los Angeles, announced that they had successfully used stem cells to restore vision in mice with retinal degeneration. The researchers hope to begin human clinical trials in the near future.
  • In 2019, the U.S. Food and Drug Administration approved a new drug called Beovu for the treatment of wet age-related macular degeneration, a common retinal disorder that can lead to vision loss. Beovu works by targeting a protein called VEGF, which can cause abnormal blood vessel growth in the retina. The drug has been shown to be effective at reducing the progression of the disease and improving vision in people with wet age-related macular degeneration.

Report Scope:

In this report, Global Retinal Disorder Treatment Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Retinal Disorder Treatment Market, By Type:

  • Macular Degeneration
  • Diabetic Retinopathy
  • Others

Retinal Disorder Treatment Market, By Dosage Form:

  • Gels
  • Eye Solution
  • Capsules & Tablets
  • Eye Drops
  • Others

Retinal Disorder Treatment Market, By Distribution Channel:

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Retinal Disorder Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Retinal Disorder Treatment Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Retinal Disorder Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Macular Degeneration, Diabetic Retinopathy, Others)
    • 5.2.2. By Dosage Form (Gels, Eye Solution, Capsules & Tablets, Eye Drops, Others)
    • 5.2.3. By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
    • 5.2.4. By Region
    • 5.2.5. By Company (2022)
  • 5.3. Product Map
    • 5.3.1. By Type
    • 5.3.2. By Dosage Form
    • 5.3.3. By Distribution Channel
    • 5.3.4. By Region

6. North America Retinal Disorder Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Dosage Form
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Retinal Disorder Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Dosage Form
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Retinal Disorder Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Dosage Form
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Retinal Disorder Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Dosage Form
        • 6.3.3.2.3. By Distribution Channel

7. Europe Retinal Disorder Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Dosage Form
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Retinal Disorder Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Dosage Form
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. Germany Retinal Disorder Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Dosage Form
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Retinal Disorder Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Dosage Form
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Retinal Disorder Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Dosage Form
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Retinal Disorder Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Dosage Form
        • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Retinal Disorder Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Dosage Form
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Retinal Disorder Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Dosage Form
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Retinal Disorder Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Dosage Form
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Retinal Disorder Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Dosage Form
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Retinal Disorder Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Dosage Form
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Retinal Disorder Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Dosage Form
        • 8.3.5.2.3. By Distribution Channel

9. South America Retinal Disorder Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Dosage Form
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Retinal Disorder Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Dosage Form
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Argentina Retinal Disorder Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Dosage Form
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. Colombia Retinal Disorder Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Dosage Form
        • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Retinal Disorder Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Dosage Form
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Retinal Disorder Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Dosage Form
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Saudi Arabia Retinal Disorder Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Dosage Form
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. UAE Retinal Disorder Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Dosage Form
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Type Launches

13. Global Retinal Disorder Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Types

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Type Offerings
  • 15.3. Recent Developments
  • 15.4. Key Personnel
  • 15.5. SWOT Analysis
    • 15.5.1. Santen Pharmaceutical Co. Ltd.
    • 15.5.2. Regeneron Pharmaceuticals Inc.
    • 15.5.3. Graybug Vision, Inc.
    • 15.5.4. Shire (Takeda Pharmaceutical Company Limited)
    • 15.5.5. Bayer AG
    • 15.5.6. Genentech, Inc.
    • 15.5.7. Acucela Inc.
    • 15.5.8. Pfizer, Inc.
    • 15.5.9. Kubota Pharmaceutical Holdings Co., Ltd.
    • 15.5.10. Allergan plc. (AbbVie Inc.)

16. Strategic Recommendations